NEW YORK (GenomeWeb) – German molecular diagnostics firm New Oncology today announced a collaboration with the University Hospital Oslo aimed at guiding treatment of patients with targeted cancer therapies.

Financial details of the agreement weren't disclosed, but New Oncology, the molecular diagnostics division of genomic analytics firm Blackfield, said that under the collaboration it will use its next-gen sequencing diagnostic platform, Neo, to identify alterations in cancer-related genes that predict a patient's response or resistance to targeted therapies.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.